AERA Health provides a platform that integrates insights from leading medical professionals and functional medicine principles into a centralized intelligence center, utilizing AI to enhance patient-centered care. The technology addresses the fragmentation in healthcare delivery by automating routine tasks and enabling personalized treatment plans, resulting in improved patient outcomes and increased administrative efficiency.

Alto Neuroscience develops precision medicines for neuropsychiatric conditions using an AI-driven biomarker platform to predict clinical responses and identify patients most likely to benefit from their drug candidates. Their focus on major depressive disorder, bipolar depression, and schizophrenia aims to replace the trial-and-error approach in psychiatric treatment with targeted therapies based on deep neurobiological insights.

Booster Therapeutics develops small molecules that activate the 20S proteasome to enhance cellular protein degradation, addressing the dysfunction that leads to the accumulation of damaged proteins in aging and neurodegenerative diseases. By restoring proteasome activity, their approach aims to improve cellular resilience and reduce the impact of complex diseases associated with impaired protein homeostasis.

Cambrian Bio is a clinical-stage drug development company focused on creating therapeutics that target the biological mechanisms of aging to prevent chronic diseases. By collaborating with leading scientists, Cambrian aims to develop effective and safe therapies that extend healthspan and improve patient outcomes.

The startup develops intensive drug therapies targeting age-related diseases through advanced drug discovery techniques and comprehensive support services. By focusing on extending human lifespan, the company aims to provide effective treatments that enhance health and longevity.

Cleara is developing peptide-based therapeutics that selectively eliminate "scarred" senescent cells associated with chronic diseases and late-stage cancers, utilizing a proprietary platform technology to target specific cellular pathways. Their lead candidates, CL04177 and CL04183, demonstrate effective clearance of these cells in preclinical models, aiming to advance precision medicine for metastatic colon and triple-negative breast cancers.

Gameto is a biotechnology company utilizing cell engineering to develop therapeutics for women's reproductive health, focusing on improving in vitro fertilization (IVF) and egg freezing processes. The company addresses significant gaps in fertility treatments and aims to enhance patient outcomes through its innovative platform.

Refoxy Pharmaceuticals develops small molecule activators targeting the FOXO3 transcription factor to treat age-related diseases, particularly Idiopathic Pulmonary Fibrosis. By enhancing FOXO3 activity, the company aims to improve cellular homeostasis and combat fibrotic and cardiovascular disorders, addressing the need for effective therapies in these complex conditions.

Samsara Therapeutics develops therapeutics for age-related neurodegenerative diseases by focusing on the activation of autophagy pathways. The company utilizes an in-house phenotypic screening platform with patient-derived iPSCs to identify small molecule autophagy activators. This approach aims to delay disease progression in conditions such as ALS, Parkinson's Disease, and CMT.

Storypod provides an interactive audio system designed for early childhood development through screen-free engagement. The platform offers adaptive, stage-based content curated by educators to boost cognitive skills via language-rich play. This system supports children from infancy through early school age with a growing library of audio content and recording capabilities.